Contact Us

Day: December 5, 2019

53Biologics protein biosimilar biologic

C1-Expressed Biosimilar Breakthrough

December 5, 2019

We’re thrilled to announce our latest endeavor: the research and development of a C1-expressed biosimilar certolizumab for the treatment of inflammatory diseases. This groundbreaking project, generously funded by the ERDF of the European…

Read More »
Privacy Overview

This website uses cookies so that we can provide you with the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our site or helping our team understand which sections of the site you find most interesting and useful.